183 related articles for article (PubMed ID: 25129332)
21. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
[TBL] [Abstract][Full Text] [Related]
22. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
Miller D; Chang JS; Flynn HW; Alfonso EC
J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
[TBL] [Abstract][Full Text] [Related]
24. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
Wallrauch C; Voss A; Milatovic D; Braveny I
Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
[TBL] [Abstract][Full Text] [Related]
25. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
Goldstein EJC; Citron DM; Warren YA; Tyrrell KL; Rybak MJ
J Med Microbiol; 2008 Apr; 57(Pt 4):452-456. PubMed ID: 18349364
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Smith KR; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
[TBL] [Abstract][Full Text] [Related]
27. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
[TBL] [Abstract][Full Text] [Related]
28. Activity of eight fluoroquinolones against both methicillin-susceptible and -resistant Staphylococcus aureus isolated from skin infections.
Nishijima S; Namura S; Akamatsu H; Kawai S; Asada Y; Kawabata S; Fujita M
J Dermatol; 1995 Feb; 22(2):153-5. PubMed ID: 7722093
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
30. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
31. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
[TBL] [Abstract][Full Text] [Related]
32.
Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
[TBL] [Abstract][Full Text] [Related]
33. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.
Chen YH; Liu CY; Ko WC; Liao CH; Lu PL; Huang CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2014 Feb; 33(2):233-9. PubMed ID: 23955154
[TBL] [Abstract][Full Text] [Related]
34. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
[TBL] [Abstract][Full Text] [Related]
35. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
Al-Nawas B; Shah PM
J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
[TBL] [Abstract][Full Text] [Related]
36. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
37. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
38. Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871
Ding L; Yang Y; Zheng C; Sun G; Han R; Guo Y; Yin D; Wu S; Zhu D; Hu F
Microbiol Spectr; 2022 Dec; 10(6):e0171522. PubMed ID: 36326536
[TBL] [Abstract][Full Text] [Related]
39. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
40. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
